Single Agent Temsirolimus (Torisel®) in Chemotherapy-naïve Castration-Resistant Prostate Cancer Patients

• To evaluate the time to disease progression [ Time Frame: Proportion of patients alive at 1, 2 and 3 years ] [ Designated as safety issue: No ]
• To investigate the toxicity and tolerability using the NCI CTCAE criteria [ Time Frame: throughout the time the patient is on study ] [ Designated as safety issue: Yes ]
• To evaluate the time to systemic chemotherapy and time to alternative therapy [ Time Frame: actual day patient starts next treatment ] [ Designated as safety issue: No ]
• To assess the changes in PSA doubling time before and after treatment [ Time Frame: evaluate time frame using dates and actual PSA values ] [ Designated as safety issue: No ]
• Biochemical responses measured by serum PSA changes [ Time Frame: Using actual PSA values and dates from start of study - lasting through out study ] [ Designated as safety issue: No ]
• Proportion of patients alive at 1, 2, & 3 years [ Time Frame: use actual data ] [ Designated as safety issue: No ]
• Impact of treatment on quality of life (QOL) and pain scores using the MDASI & BPI published scales [ Time Frame: baseline, C3 & C5 ] [ Designated as safety issue: No ]

This is a single institution, open label, phase II study in androgen-independent prostate cancer patients who are chemotherapy-naïve. Patients will receive Torisel® 25 mg weekly. Treatment continues until disease progression, patient's withdrawal, unacceptable toxicity or the investigator's discretion.

This is an open label phase II study conducted in patients who have androgen-independent and castration-resistant prostate cancer but who have not received systemic chemotherapy. Investigational therapy such as vaccines, immunotherapy, and some oral targeted agents are NOT considered chemotherapy. Prior use of steroids is not an exclusion criterion.

Patients who meet the inclusion criteria will be allowed to participate. Enrolled patients will receive single agent Torisel® at 25 mg weekly. Every 4 weeks of therapy will constitute one cycle of treatment. Patients will continue on therapy until voluntary withdrawal, toxicity, progression, or the investigator's discretion. Patients will be followed for 3 years after discontinuation of Torisel®.

Patients are allowed to receive intravenous or oral bisphosphonates for their bone metastases and are advised to continue androgen blockade while on study.

Inclusion Criteria:

1. Understand and voluntarily sign an informed consent form.
2. Age 18 years at the time of signing the informed consent form.
3. Able to adhere to the study visit schedule and other protocol requirements.
4. Documented prostate cancer regardless of the Gleason score
5. Patients should be considered hormone refractory and castration-resistant. They must fail LHRH analogues, and anti-androgen withdrawal trial. Failure is confirmed by an increase in PSA value of 10% or more than the value immediately before.
6. Patients must have measurable disease either biochemically (using PSA) and/or using the RECIST criteria for visceral organ involvement and/or bone disease. If there is no disease to follow on scans a PSA value of at least 5 ng per milliliter needs to be present at baseline to be evaluated for PSA response.
7. ECOG Performance Status of 2 or less.
8. Adequate liver function tests with ALT/AST being < 3x normal, total bilirubin of 1.5 or less, and adequate renal function measured by a creatinine of 2.0 mg/dl or less. Alkaline phosphatase values are never exclusion criteria if it is deemed related to bone metastases.

9. Patients need to have adequate bone marrow function.

   • ANC of 1000 or above,
   • Hgb of 9.0 g/dl or above,
   • Platelets of 100,000 or above. If other causes are affecting plts counts such as autoimmune disorders, patients are allowed on study. Patients with inadequate bone marrow function that is deemed related to bone marrow involvement with prostate cancer (cytopenias are due to extensive marrow infiltration with prostate cancer) are allowed at the investigator's discretion.
10. Patients with other malignancies are allowed as long as there is no evidence of the other malignancy present at entry time, and it has been 3 years or more since the treatment for the other disorder was completed. Patients with non-melanoma skin cancers are allowed to participate in the study.
11. Investigational therapy such as vaccines, immunotherapy, and oral targeted agents are allowed on this study as long as their last exposure was 4 weeks prior to study entry. These agents are not considered an exclusion criteria as they are not considered standard chemotherapy.
12. Patients with known bone metastases are allowed to receive intravenous bisphosphonates such as aredia or zometa. Patients on oral bisphosphonates are also allowed.
13. All study participants are encouraged to continue androgen deprivation with an LHRH analogue.
14. Patients must agree to use a latex condom during sexual contact with a female of childbearing potential, even if they have had a successful vasectomy and despite the fact that they are on androgen deprivation.
15. Last treatment for prostate cancer should be at least 4 weeks ago

Exclusion Criteria:

1. Prior systemic chemotherapy for CRPC
2. Prior exposure to TEM
3. Known HIV positive status or infectious hepatitis, type A, B, or C.
4. Known brain metastases.
5. Steroids are allowed concomitantly ONLY IF they are taken for another chronic medical condition (Such as COPD, Multiple sclerosis…etc)
6. Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing and understanding the informed consent form.
7. Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he were to participate in the study or confounds the ability to interpret data from the study.
8. Use of any other experimental drug or therapy within 28 days of baseline.